Literature DB >> 21803873

Lesions by tissue specific imaging characterize multiple sclerosis patients with more advanced disease.

Francesca Bagnato1, Vasiliki N Ikonomidou, Peter van Gelderen, Sungyoung Auh, Jailan Hanafy, Fredric K Cantor, Joan Ohayon, Nancy Richert, Jeff Duyn.   

Abstract

BACKGROUND: Cerebrospinal fluid tissue specific imaging (CSF-TSI), a newly implemented magnetic resonance imaging (MRI) technique, allows visualization of a subset of chronic black holes (cBHs) with MRI characteristics suggestive of the presence of CSF-like fluid, and representing lesions with extensive tissue destruction.
OBJECTIVE: To investigate the relationship between lesions in CSF-TSI and disease measures in patients with multiple sclerosis (MS).
METHODS: Twenty-six patients with MS were imaged at 3.0 T, obtaining T(1)-weighted (T(1)-w) and T(2)-w spin echo (SE), T(1) volumetric images and CSF-TSI images. We measured: (i) lesion volume (LV) in T(1)-w (cBH-LV) and T(2)-w SE images, and in CSF-TSI; (ii) brain parenchyma fraction (BPF). Differences between patients with and without CSF-TSI lesions were analyzed and association between clinical and MRI metrics were investigated.
RESULTS: cBHs were seen in 92% of the patients while lesions in CSF-TSI were seen in 40%. Patients with CSF-TSI lesions were older, with longer disease duration, higher disability scores, larger cBH-LV and T(2)-LV, and lower BPF than patients without CSF-TSI lesions (≤0.047). Partial correlation analysis correcting for T(2)-LV, cBH-LV and BPF showed an association (p < 0.0001, r = 0.753) between CSF-TSI LV and disability score.
CONCLUSIONS: CSF-TSI lesions characterize patients with more advanced disease and probably contribute to the progress of disability.

Entities:  

Mesh:

Year:  2011        PMID: 21803873     DOI: 10.1177/1352458511414601

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

1.  Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis.

Authors:  M Castellaro; R Magliozzi; A Palombit; M Pitteri; E Silvestri; V Camera; S Montemezzi; F B Pizzini; A Bertoldo; R Reynolds; S Monaco; M Calabrese
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Heterogeneity of Multiple Sclerosis White Matter Lesions Detected With T2*-Weighted Imaging at 7.0 Tesla.

Authors:  Bing Yao; Vasiliki N Ikonomidou; Fredric K Cantor; Joan M Ohayon; Jeff Duyn; Francesca Bagnato
Journal:  J Neuroimaging       Date:  2015-02-06       Impact factor: 2.486

3.  Double inversion recovery sequence of the cervical spinal cord in multiple sclerosis and related inflammatory diseases.

Authors:  I Riederer; D C Karampinos; M Settles; C Preibisch; J S Bauer; J F Kleine; M Mühlau; C Zimmer
Journal:  AJNR Am J Neuroradiol       Date:  2014-08-28       Impact factor: 3.825

4.  Evolution of tumefactive lesions in multiple sclerosis: a 12-year study with serial imaging in a single patient.

Authors:  Vasiliki N Ikonomidou; Nancy D Richert; Alexander Vortmeyer; Fernanda Tovar-Moll; Bibiana Bielekova; Natalie E Cook; Jeff H Duyn; Francesca Bagnato
Journal:  Mult Scler       Date:  2013-10       Impact factor: 6.312

5.  Semi-automated method for estimating lesion volumes.

Authors:  Hyun-Joo Park; Andre G Machado; Jessica Cooperrider; Havan Truong-Furmaga; Matthew Johnson; Vibhuti Krishna; Zhihong Chen; John T Gale
Journal:  J Neurosci Methods       Date:  2012-12-20       Impact factor: 2.390

6.  Generalized min-max bound-based MRI pulse sequence design framework for wide-range T1 relaxometry: A case study on the tissue specific imaging sequence.

Authors:  Yang Liu; John R Buck; Vasiliki N Ikonomidou
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

7.  Probing axons using multi-compartmental diffusion in multiple sclerosis.

Authors:  Francesca Bagnato; Giulia Franco; Hua Li; Enrico Kaden; Fei Ye; Run Fan; Amalie Chen; Daniel C Alexander; Seth A Smith; Richard Dortch; Junzhong Xu
Journal:  Ann Clin Transl Neurol       Date:  2019-08-13       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.